A light-activated drug to fight psoriasis
The therapeutic efficacy of a new compound against psoriasis is confirmed
A light-activated drug to fight psoriasis Read More »
The therapeutic efficacy of a new compound against psoriasis is confirmed
A light-activated drug to fight psoriasis Read More »
The event will take place on Thursday, February 6, at the Barradas Auditorium in L’Hospitalet and will commemorate the International Day of Women and Girls in Science.
A multifaceted look at the role of women in biomedical research will be the focus of this year’s sLHam, which will talk about women as researchers and as researched.
In its 8th edition, the sLHam will have two sessions, a morning session for students and an afternoon session for the general public.
Aptadel Therapeutics receives half a million dollars for a preclinical research program against Ewing’s sarcoma.
New investment in the research against Ewing’s sarcoma Read More »
A multicenter collaboration leaded by the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Germans Trias i Pujol Research Institute (IGTP) identified a potential new treatment for an aggressive sarcoma arising in the nerves. The findings have been published in the journal Clinical Cancer Research.
The conference fostered interactions between both research areas to generate new synergies and nurture existing ones.
The study underscores the importance of increasing vaccination in adults to prevent invasive pneumococcal disease, especially in risk groups (older adults and/or those with comorbidities).
There is a need to continue developing and improving pneumococcal vaccines to expand their coverage, given the great capacity of these pathogens to adapt.
IDIBELL researchers identify key factors in Ewing’s sarcoma metastasis
Step forward in the understanding of Ewing sarcoma Read More »
Two IDIBELL researchers receive financial support to consolidate and enhance the internationalization of their research
This large-scale nutrimetabolomic analysis, one of the most extensive to date, underscores the relevance of dietary factors and the gut microbiome in prostate cancer risk.
The study has been led by the Bellvitge Biomedical Research Institute (IDIBELL), the University of Barcelona and the CIBER on Frailty and Healthy Ageing (CIBERFES).